Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Publication Type:

Journal Article

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 26, Issue 4, p.626-32 (2008)

Keywords:

2008, Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Follow-Up Studies, Gastrointestinal Stromal Tumors, Humans, Male, Middle Aged, Piperazines, Prognosis, Proto-Oncogene Proteins c-kit, Public Health Sciences Division, Pyrimidines, Retrospective Studies, Survival Rate

Abstract:

To assess potential differences in progression-free or overall survival when imatinib mesylate is administered to patients with incurable gastrointestinal stromal tumors (GIST) at a standard dose (400 mg daily) versus a high dose (400 mg twice daily).